Collaboration Between Tempus and Genialis - Tempus AI Inc (TEM) announced a multi-year collaboration with Genialis to leverage Tempus' multimodal dataset for developing RNA-based algorithms across cancer types [1] - The partnership combines Tempus' expertise in clinical and molecular data with Genialis' AI-driven analytics to improve diagnostics and personalized treatments in precision medicine [2] - The collaboration enhances Tempus' offerings in precision medicine through AI-driven RNA biomarker development, potentially attracting more partnerships and increasing revenue potential [3] Impact on TEM Stock and Financials - Following the announcement, TEM shares declined 3.5% to close at 6.12 billion, with Zacks Consensus Estimate projecting fiscal 2024 revenues of 19.27 billion in 2023 and is expected to grow at a CAGR of 38.5% from 2024 to 2030 [9] - The adoption of digital technologies in healthcare is driven by the need to reduce costs and enhance patient-care services, boosting the growth of AI in the healthcare market [10] TEM's Zacks Rank and Peer Comparison - TEM carries a Zacks Rank 2 (Buy) at present [11] - Masimo (MASI) has an estimated growth rate of 11.8% for 2025, with shares rising 31.7% against the industry's 1% decline in the past six months [11][12] - Accuray (ARAY) has an estimated growth rate of 1200% for 2025, with shares gaining 8.8% against the industry's 1% decline in the past six months [12][13] - Abbott Laboratories (ABT) has an estimated earnings growth rate of 10% for 2025, with shares rising 8.5% in the past six months compared to the industry's 7.2% growth [13]
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis